Background: Hepatitis B is an important infectious disease.  Since several years ago, mass vaccination against this viral infection has become as part of routine vaccination schedule of Iran.  However, some healthy neonates, children and adults fail to generate a protective antibody response after vaccination.Objectives: To investigate distribution of HLA class-I and class-II antigens in health...

Background & Objectives: Hepatitis B is one of the major health problems in the world. Health care workers (HCWs) are at high risk of acquiring hepatitis B virus. The aim of this study was to evaluate the prevalence of HBV infection and the immune response to HBV vaccine among the HCWs in Babol, northern...

Hepatitis B virus (HBV) is a serious global health problem. The development of a safe and effective vaccinewould help infection prevention. Previous hepatitis B vaccine production involved the isolation of the noninfectious particle from chronic HBV carriers. DNA recombinant technology has been used for vaccineproduction without having been contaminated with blood-born infectious ag...

BACKGROUND Hepatitis B vaccine and hepatitis B immunoglobulin are considered for newborn infants of HBsAg-positive mothers to prevent hepatitis B infection. OBJECTIVES To assess the beneficial and harmful effects of hepatitis B vaccines and hepatitis B immunoglobulin in newborn infants of HBsAg-positive mothers. SEARCH STRATEGY Trials were identified through The Cochrane Neonatal Group Cont...

BACKGROUND & OBJECTIVES Conventional hepatitis B vaccine protocols do not provide rapid seroprotection against hepatitis B. This randomized controlled trial was carried out to investigate the efficacy of granulocyte macrophage-colony stimulating factor (GM-CSF) augmented double-dose vaccine protocol in voluntary kidney donors prior to donor nephrectomy. METHODS A total of 54 kidney donors, wh...

Objective: To compare immunogenicity of a recombinant hepatitis B (HB) vaccine in two groups of neonates born in two cities of Iran with different geographic and ethnic backgrounds.   Materials and Methods: Ten micrograms of a recombinant HB vaccine was administered under field condition to Iranian healthy neonates at 0, 1.5 and 9 months intervals. The subjects consisted of two groups of 290 an...

INTRODUCTION Hepatitis B vaccination starting at birth provides a safety net for infants exposed to hepatitis B virus (HBV) during delivery or in early life. Hepatitis B vaccine is recommended in the United States for infants prior to birthing facility discharge, and within the first 12h of life for infants born to hepatitis B surface antigen (HBsAg)-positive mothers. We performed a literature ...

NL Biotechnologies is a biotech R&D company that specializes in viral Hepatitis B, C, and E vaccine development. The proprietary recombinant Hepatitis B vaccine technology has been commercialized in 2002 by Instituto Butantan (Brazil) and in 2004 by Probiomed S.A. de C.V. (Mexico). The overall sales exceed 200 million doses. Since 2001, NL Biotechnologies in collaboration with CDC (US, Atlanta)...